Brain-derived neurotrophic factor (BDNF) is often called "Miracle-Gro for the brain" — a neurotrophin that promotes the survival, growth, and differentiation of neurons and synapses. Low BDNF levels are associated with depression, cognitive decline, and neurodegenerative disease. Semax, a synthetic analogue of ACTH(4-7), is one of the most potent known upregulators of BDNF expression.
Mechanism: From Receptor to Gene Expression
Semax binds to melanocortin receptors (MC4R in particular) in the central nervous system. This binding triggers a cascade involving cAMP elevation, PKA activation, and ultimately CREB phosphorylation — a transcription factor that drives BDNF gene expression. The result is a rapid and sustained increase in BDNF protein levels in the hippocampus and prefrontal cortex, regions critical for memory and executive function.
Clinical Context
Semax has been approved in Russia since 1996 for the treatment of ischemic stroke, transient ischemic attacks, and optic nerve disease. It is administered intranasally in clinical settings, with doses typically ranging from 300–900 mcg per day.
Dopaminergic and Serotonergic Modulation
Beyond BDNF, Semax modulates monoamine neurotransmitter systems. It increases dopamine turnover in the striatum and prefrontal cortex, contributing to improved motivation, focus, and working memory. Serotonergic effects include increased 5-HT synthesis and release, which may underlie the anxiolytic and mood-stabilizing properties reported in some studies.
- BDNF upregulation in hippocampus and PFC
- NGF (nerve growth factor) elevation
- Dopamine turnover increase in striatum
- Serotonin synthesis enhancement
- Anti-inflammatory via NF-κB inhibition
Neuroprotective Effects in Ischemia
Semax's most clinically validated application is neuroprotection following ischemic stroke. Multiple clinical trials have demonstrated reduced neurological deficit scores, faster functional recovery, and improved cognitive outcomes when Semax is administered within the first 24 hours of stroke onset. The mechanism involves both BDNF-mediated neuronal survival and direct anti-inflammatory effects that reduce the ischemic penumbra.
| Effect | Mechanism | Evidence Level |
|---|---|---|
| Memory enhancement | BDNF, hippocampal LTP | Preclinical + Clinical |
| Neuroprotection | BDNF, anti-inflammatory | Clinical (stroke) |
| Anxiolysis | Serotonin, GABA modulation | Preclinical |
| Focus/attention | Dopamine, norepinephrine | Preclinical |
Intranasal Delivery and Bioavailability
Semax is typically administered intranasally, which allows direct access to the CNS via the olfactory nerve pathway, bypassing the blood-brain barrier. This route achieves significantly higher CNS concentrations than systemic injection for the same dose. The peptide has a short plasma half-life (~20 minutes) but produces CNS effects lasting several hours, suggesting receptor-mediated downstream signaling rather than direct peptide action.
Conclusion
Semax stands out in the nootropic peptide landscape for its combination of clinical validation, well-characterized mechanism, and favorable safety profile. Its BDNF-upregulating properties make it particularly interesting for research into cognitive enhancement, neuroprotection, and the treatment of neurodegenerative conditions.
Tags
Research Use Only. All content on peptid.ai is intended for informational and research purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment. Peptides sold by peptidAI are for laboratory research use only and are not approved for human consumption.